In an exclusive interview, Jarbas Barbosa da Silva, Director-President of the Brazilian Health Regulatory Agency (ANVISA), discusses some of the key specificities of the Brazilian market and highlights some of the main regulatory updates implemented by ANVISA over the past two years, while providing insights into the collaboration opportunities he envisions for international regulatory agencies, a few months after ANVISA officially became a regulatory member of the prestigious International Conference on Harmonization (ICH).
What are some of the unique specificities of the Brazilian market that you take into account when strengthening the country’s regulatory framework?
"Brazil is the sixth largest pharmaceutical market in the world and we are steadily moving toward the fifth position, which we will probably reach within the upcoming years."
